Psychiatry & Neurology, Clinical Neurophysiology · Fair Lawn, NJ
NPI
1154372621
Since 2006
Specialty
Psychiatry & Neurology, Clinical Neurophysiology
Code 2084N0600X
Group practices
16
Medicare group memberships
Hospitals
5
Hospital affiliations
14-01 Broadway Ste B
Fair Lawn, NJ, 07410
Phone (201) 791-4544
Groups this clinician bills Medicare through
Medicare paid, 2024
$226K
4,545 services
Medicare patients, 2024
341
Average age 71
Drug cost, 2024
$25.4M
3,548 prescriptions
Company payments, 2025
$57K
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nilay R Shah was code 99213 (office e&m - established), 359 times for 182 patients. In total Nilay R Shah billed 4,545 services in 39 codes, and Medicare paid $226K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 359 | 182 | $74.56 | $27K |
| 95886 Electrical Nerve Conductivity | Office | 166 | 74 | $85.32 | $14K |
| 95913 Electrical Nerve Conductivity | Office | 84 | 74 | $247.98 | $21K |
| 95720 Neurologic | Office | 70 | 24 | $175.27 | $12K |
| 95716 Neurologic | Office | 70 | 24 | $1,015.59 | $71K |
| 95813 Neurologic | Office | 69 | 69 | $395.59 | $27K |
| 99214 Office E&M - Established | Office | 48 | 42 | $105.96 | $5,086 |
| 99204 Office E&M - New | Office | 40 | 40 | $135.72 | $5,429 |
| 99203 Office E&M - New | Office | 29 | 29 | $92.28 | $2,676 |
| 99231 Hospital E&M - Subsequent | Facility | 27 | 24 | $42.53 | $1,148 |
| 95700 Neurologic | Office | 24 | 24 | $203.15 | $4,876 |
By year: 2022 $345K for 4,713 services; 2023 $290K for 5,465 services; 2024 $226K for 4,545 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nilay R Shah prescribed most often to Medicare patients was Octagam (Immun Globg(Igg)/Malt/Iga Ov50), with 463 prescriptions and refills. In total Nilay R Shah wrote 3,548 Medicare prescriptions that cost $25.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 463 | 469 | 46 | $10.7M |
| Memantine Hcl Generic | 359 | 701 | 107 | $11K |
| Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 | 355 | 355 | 37 | $7.8M |
| Donepezil Hcl Generic | 232 | 574 | 73 | $2,161 |
| Gabapentin Generic | 230 | 349 | 83 | $4,049 |
| Lamotrigine Generic | 203 | 384 | 56 | $2,866 |
| Sodium Chloride 0.9 % Sodium Chloride | 148 | 148 | 62 | $975 |
| Gammaked Immune Globul G/Gly/Iga Avg 46 | 120 | 120 | 14 | $3.6M |
| Carbidopa-Levodopa Carbidopa/Levodopa | 109 | 221 | 33 | $1,513 |
| Levetiracetam Generic | 106 | 187 | 29 | $4,154 |
| Quetiapine Fumarate Generic | 91 | 172 | 30 | $1,350 |
| Amantadine Amantadine Hcl | 76 | 152 | 27 | $4,927 |
| Amitriptyline Hcl Generic | 66 | 103 | 24 | $789 |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 56 | 56 | Under 11 | $1.0M |
| Xcopri Cenobamate | 55 | 55 | Under 11 | $62K |
Brand drugs: 1,458 claims; generic drugs: 2,090 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nilay R Shah $57K ($57K in general payments such as food, travel and fees) from 28 companies. The largest payer was TG Therapeutics, Inc. with $46K.
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. TGTX | 32 | $46K |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $5,605 |
| Kedrion Biopharma, Inc. | 1 | $2,000 |
| SK Life Science, Inc. | 6 | $1,410 |
| Axsome Therapeutics, Inc. AXSM | 11 | $432 |
| Amgen Inc. AMGN | 4 | $222 |
| Argenx US, Inc. ARGX | 2 | $222 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $174 |
| Vanda Pharmaceuticals Inc. VNDA | 4 | $165 |
| Teva Pharmaceuticals USA, Inc. TEVA | 11 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.